A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2595-2603

  Yuen, Kevin C J ^a   Conway, Gerard S ^b   Popovic, Vera ^c,d   Merriam, George R ^e   Bailey, Timothy ^f   Hamrahian, Amir H ^g   Biller, Beverly M K ^h   Kipnes, Mark ⁱ   Moore, Jerome A ^j   Humphriss, Eric ^k   Bright, George M ^k   Cleland, Jeffrey L ^k  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f AMCR Institute   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ Endocrinology Practice   (United States)

^j Pacific Biodevelopment LLC   (United States)

^k Versartis Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE DERIVATIVE; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG; VRS 317;

ADULT; AGED; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE FATIGUE; MYALGIA; NORTH AMERICA; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED;

EID: 84878499352     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1437     Document Type: Article

References (38)

1. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14:143-154.
2. Desrosiers P, O'Brien F, Blethen S. Patient outcomes in the GH-Monitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev. 2005;3(2 suppl):327-331. (Pubitemid 40469491)
3. Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93:147-148. (Pubitemid 351204756)
4. Hunter I, de Vries C, Morris A, MacDonald T, Greene SA. Human growth hormone therapy: poor adherence equals poor growth. Arch Dis Child. 2000;82(suppl 1):A8.
5. Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children iscommonand impairs linear growth. PLoS One. 2011;6:e16223.
6. Lippe B, Frasier SD, Kaplan SA. Use of growth hormone-gel. Arch Dis Child. 1979;54:609-613. (Pubitemid 9218602)
7. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM. A long-acting human growth hormone (Nutropin depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab. 2002;15:715-722. (Pubitemid 34700345)
8. Hoffman AR, Biller BM, Cook D, et al. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab. 2005;90:6431-6440. (Pubitemid 41759296)
9. Kemp SF, Fielder PJ, Attie KM, et al. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin depot) in GH-deficient children. J Clin Endocrinol Metab. 2004;89:3234-3240. (Pubitemid 38951887)
10. Cook DM, Biller BM, Vance ML, et al. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin depot) in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:4508-4514. (Pubitemid 35251858)
11. Biller BM, Ji HJ, Ahn H, et al. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab. 2011;96:1718-1726.
12. Péter F, Bidlingmaier M, Savoy C, Ji HJ, Saenger PH. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab. 2012;97:400-407.
13. Fares F, Guy R, Bar-Ilan A, Felikman Y, Fima E. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH. Endocrinology. 2010;151:4410-4417.
14. Søndergaard E, Klose M, Hansen M, et al. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab. 2011;96:681-688.
15. de Schepper J, Rasmussen MH, Gucev Z, Eliakim A, Battelino T. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. Eur J Endocrinol. 2011;165:401-409.
16. Ferrandis E, Pradhananga SL, Touvay C, et al. Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions. Clin Sci (Lond). 2010;119:483-491.
17. Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab. 2010;95:3411-3417.
18. Bidlingmaier M, Kim J, Savoy C, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab. 2006;91:2926-2930. (Pubitemid 44271737)
19. Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27:1186-1190.
20. Cleland JL, Geething NC, Moore JA, et al. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life. J Pharm Sci. 2012;101:2744-2754.
21. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
22. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009;15(suppl 2):1-29.
23. Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94:2702-2707.
24. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 4. evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed May 1, 2013.
25. Draize JH, Woodward G, Calvary HO. methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377-390.
26. Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157:695-700.
27. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72:374-381. (Pubitemid 21921702)
28. Drake WM, Coyte D, Camacho-Hübner C, et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab. 1998;83:3913-3919. (Pubitemid 28513572)
29. Hoffman AR, Strasburger CJ, Zagar A, et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab. 2004;89:3224-3233. (Pubitemid 38960691)
30. Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J Clin Endocrinol Metab. 2012;97:E521-E527.
31. Spina LD, Soares DV, Brasil RR, et al. Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement. Growth Horm IGF Res. 2004;14:45-51. (Pubitemid 38088778)
32. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf). 2004;60:442-450. (Pubitemid 38482506)
33. Bülow B, Link K, Ahrén B, Nilsson AS, Erfurth EM. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf). 2004;61:683-691. (Pubitemid 40011843)
34. Yuen KC, Dunger DB. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab. 2007;9:11-22. (Pubitemid 44921037)
35. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol. 2005;152:67-75. (Pubitemid 40192469)
36. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152-177.
37. Christopher M, Hew FL, Oakley M, Rantzau C, Alford F. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J Clin Endocrinol Metab. 1998;83:1668-1681. (Pubitemid 28501041)
38. Johannsson G. Long-acting growth hormone for replacement therapy. J Clin Endocrinol Metab. 2011;96:1668-1670.